Does B-type natriuretic peptide-guided therapy improve outcomes in patients with chronic heart failure? A systematic review and meta-analysis of randomized controlled trials
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 605478643 | ||
| 003 | CHVBK | ||
| 005 | 20210128100406.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 210128e20150101xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1007/s10741-014-9437-8 |2 doi |
| 035 | |a (NATIONALLICENCE)springer-10.1007/s10741-014-9437-8 | ||
| 245 | 0 | 0 | |a Does B-type natriuretic peptide-guided therapy improve outcomes in patients with chronic heart failure? A systematic review and meta-analysis of randomized controlled trials |h [Elektronische Daten] |c [Wei Xin, Zhiqin Lin, Shuhua Mi] |
| 520 | 3 | |a The role of B-type natriuretic peptide (BNP) in the management of patients with chronic heart failure (CHF) was uncertain. The aim of this meta-analysis was to comprehensively evaluate the effect of BNP-guided therapy in CHF. Relevant randomized controlled trials were identified by searching of Pubmed, Embase and the Cochrane Library databases. Fixed or randomized effect models were applied to combine the data according to the heterogeneity of the included studies. Fourteen studies with 3,004 CHF patients were included. Results of our meta-analyses suggested that compared with clinical group, BNP-guided treatment significantly decreased the risk of heart failure-related hospitalization (RR 0.79, 95% CI 0.63-0.98, p=0.03), although did not significantly affect the risk of all-cause mortality (RR 0.94, 95% CI 0.81-1.08, p=0.39) or all-cause hospitalization (RR 0.97, 95% CI 0.89-1.07, p=0.56). Furthermore, between-group BNP changes seemed to be a significant modifier to the effects of BNP-guided therapy on clinical outcomes, and BNP-guided therapy may improve the clinical outcomes of CHF patients if substantial reduction of BNP can be achieved. In addition, BNP-guided therapy was not associated with increased risk for serious adverse events. BNP-guided therapy may improve the clinical outcomes of CHF patients if substantial reduction of BNP can be achieved. BNP-guided therapy seemed to be safe and promising for CHF patients, and future studies with well-designed BNP-guided medication up-titration strategies are needed to confirm these results. | |
| 540 | |a Springer Science+Business Media New York, 2014 | ||
| 690 | 7 | |a B-type natriuretic peptide |2 nationallicence | |
| 690 | 7 | |a N-terminal pro-B-type natriuretic peptide |2 nationallicence | |
| 690 | 7 | |a Chronic heart failure |2 nationallicence | |
| 690 | 7 | |a Meta-analysis |2 nationallicence | |
| 690 | 7 | |a CHF : Chronic heart failure |2 nationallicence | |
| 690 | 7 | |a BNP : B-type natriuretic peptide |2 nationallicence | |
| 690 | 7 | |a NT-proBNP : N-terminal pro-B-type natriuretic peptide |2 nationallicence | |
| 690 | 7 | |a HF : Heart failure |2 nationallicence | |
| 690 | 7 | |a ACEIs : Angiotensin-converting enzyme inhibitors |2 nationallicence | |
| 690 | 7 | |a ARBs : Angiotensin II receptor blockers |2 nationallicence | |
| 690 | 7 | |a AAs : Aldosterone antagonists |2 nationallicence | |
| 690 | 7 | |a LVEF : Left ventricular ejection fraction |2 nationallicence | |
| 690 | 7 | |a NYHA : New York Heart Association |2 nationallicence | |
| 690 | 7 | |a MLHFQS : Minnesota Living with Heart Failure Questionnaire Score |2 nationallicence | |
| 690 | 7 | |a RR : Risk ratio |2 nationallicence | |
| 690 | 7 | |a CI : Confidence interval |2 nationallicence | |
| 690 | 7 | |a WMD : Weighed mean difference |2 nationallicence | |
| 700 | 1 | |a Xin |D Wei |u Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, No. 2 Anzhen Road, Chaoyang District, 100029, Beijing, China |4 aut | |
| 700 | 1 | |a Lin |D Zhiqin |u Department of Cardiovascular Medicine, Affiliated Hospital of Guiyang Medical College, Guiyang, Guizhou, China |4 aut | |
| 700 | 1 | |a Mi |D Shuhua |u Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, No. 2 Anzhen Road, Chaoyang District, 100029, Beijing, China |4 aut | |
| 773 | 0 | |t Heart Failure Reviews |d Springer US; http://www.springer-ny.com |g 20/1(2015-01-01), 69-80 |x 1382-4147 |q 20:1<69 |1 2015 |2 20 |o 10741 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s10741-014-9437-8 |q text/html |z Onlinezugriff via DOI |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 900 | 7 | |a Metadata rights reserved |b Springer special CC-BY-NC licence |2 nationallicence | |
| 908 | |D 1 |a research-article |2 jats | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-springer | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1007/s10741-014-9437-8 |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Xin |D Wei |u Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, No. 2 Anzhen Road, Chaoyang District, 100029, Beijing, China |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Lin |D Zhiqin |u Department of Cardiovascular Medicine, Affiliated Hospital of Guiyang Medical College, Guiyang, Guizhou, China |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Mi |D Shuhua |u Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, No. 2 Anzhen Road, Chaoyang District, 100029, Beijing, China |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t Heart Failure Reviews |d Springer US; http://www.springer-ny.com |g 20/1(2015-01-01), 69-80 |x 1382-4147 |q 20:1<69 |1 2015 |2 20 |o 10741 | ||